Literature DB >> 10741626

The disposition of chloroquine and its main metabolite desethylchloroquine in volunteers with and without chloroquine-induced pruritus: evidence for decreased chloroquine metabolism in volunteers with pruritus.

O G Ademowo1, O Sodeinde, O Walker.   

Abstract

The pharmacokinetics of chloroquine and its main metabolite desethylchloroquine have been carried out in volunteers with and without chloroquine-induced pruritus. It was shown that the volunteers with pruritus tended to metabolize chloroquine slower than the volunteers without pruritus because the metabolic ratio was lower in the volunteers with pruritus than that in the volunteers without pruritus. However, the overall pharmacokinetic patterns were comparable between the two groups and agreed with published data. The 24-hour urinary collections in the two groups of volunteers indicated that the volunteers with pruritus excreted more chloroquine (although not statistically significant) than the volunteers without pruritus. This also indicates that they metabolized less chloroquine. There were no side effects of note in any of the volunteers. The volunteers who gave positive histories of chloroquine-induced pruritus had mild episodes of itching after intake of the drug; the pruritus subsided within 48 hours in all instances.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10741626     DOI: 10.1067/mcp.2000.104257

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  3 in total

1.  Effect of phytomedicines, AM-1, niprisan and nifadin on the pharmacokinetics of chloroquine in rats.

Authors:  K B Mustapha; M T Bakare-Odunola; M Garba; O O Obodozie; I S Enemali; U S Inyan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2009 Jul-Sep       Impact factor: 2.441

Review 2.  Risk Assessment of Drug-Induced Long QT Syndrome for Some COVID-19 Repurposed Drugs.

Authors:  Veronique Michaud; Pamela Dow; Sweilem B Al Rihani; Malavika Deodhar; Meghan Arwood; Brian Cicali; Jacques Turgeon
Journal:  Clin Transl Sci       Date:  2020-11-18       Impact factor: 4.689

3.  A longitudinal trial comparing chloroquine as monotherapy or in combination with artesunate, azithromycin or atovaquone-proguanil to treat malaria.

Authors:  Miriam K Laufer; Phillip C Thesing; Fraction K Dzinjalamala; Osward M Nyirenda; Rhoda Masonga; Matthew B Laurens; Abbie Stokes-Riner; Terrie E Taylor; Christopher V Plowe
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.